Tissue Regenix Group PLC Hardman & Co: Full-year 2017 - what to look for

TIDMTRX

Tissue Regenix Group PLC

08 March 2018

Hardman & Co: Full-year 2017 - what to look for

Full-year 2017: what to look for - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on expanding in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight Technologies, providing synergistic bone regeneration technology. Full-year 2017 results will be the first to reflect the acquisition and will include five months of the enlarged entity. Sales from all three business segments are forecast to be strong (total GBP5.15m). We set out our underlying growth expectations below.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/08.03.18-full-year-2017-what-to-look-for.pdf

 
 To contact us:          Contacts:       [e-mail] 
  Hardman & Co            Dr Martin       [e-mail] 
  35 New Broad Street     Hall            [e-mail] 
  London                  Dr Dorothea 
  EC2M 1NH                Hill 
  www.hardmanandco.com    Dr Gregoire 
  Follow us on Twitter    Pave 
  @HardmanandCo 
 
                          [phone] 
                          7622 
 

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAKMGGFNNGGRZM

(END) Dow Jones Newswires

March 08, 2018 02:15 ET (07:15 GMT)